Dr. Farago on Trilaciclib for Myelosuppression in Previously Treated Extensive-Stage SCLC

Cancer Network spoke with Anna F. Farago, MD, of Massachusetts General Hospital, about the effect of trilaciclib on myelosuppression in patients with previously treated extensive-stage small-cell lung cancer receiving topotecan.

Cancer Network spoke with Anna F. Farago, MD, medical oncologist at Massachusetts General Hospital, about the effect of trilaciclib, a CDK 4/6 inhibitor, on myelosuppression in patients with previously treated extensive-stage small-cell lung cancer receiving topotecan. The results (abstract 8505) were presented at ASCO 2019.